Futures
Hundreds of contracts settled in USDT or BTC
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Futures Kickoff
Get prepared for your futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to experience risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Immunic MS trial shows reduced brain lesions - ICYMI
Immunic Inc.'s chief medical officer discussed new data from the company’s phase 2 CALIPER trial for progressive multiple sclerosis (MS) at the ACTRIMS Forum. The data showed that Vidofludimus calcium, Immunic’s drug candidate, significantly reduced both acute and chronic brain lesions in MS patients, and also decreased Epstein-Barr virus (EBV) reactivation. Immunic anticipates a major year in 2026 with the readout of its Phase 3 trials in relapsing MS, which could lead to regulatory submissions and product launch.